Published in Blood Cancer J on March 22, 2013
Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms. Oncotarget (2013) 1.10
Targeting heparanase overcomes chemoresistance and diminishes relapse in myeloma. Oncotarget (2016) 0.96
Novel therapeutic strategies for multiple myeloma. Exp Hematol (2015) 0.91
Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy. Oncogene (2015) 0.90
Phospho-flow detection of constitutive and cytokine-induced pSTAT3/5, pAKT and pERK expression highlights novel prognostic biomarkers for patients with multiple myeloma. Leukemia (2014) 0.83
Activation of non-canonical TGF-β1 signaling indicates an autoimmune mechanism for bone marrow fibrosis in primary myelofibrosis. Blood Cells Mol Dis (2015) 0.79
A DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma. Blood Cancer J (2016) 0.78
Multiple Myeloma: Treatment is Getting Individualized. Indian J Hematol Blood Transfus (2015) 0.77
Integrated Drug Expression Analysis for leukemia: an integrated in silico and in vivo approach to drug discovery. Pharmacogenomics J (2016) 0.76
Combination of a Selective HSP90α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells. PLoS One (2015) 0.76
Cyclin D1 unbalances the redox status controlling cell adhesion, migration, and drug resistance in myeloma cells. Oncotarget (2016) 0.75
Prioritization of anticancer drugs against a cancer using genomic features of cancer cells: A step towards personalized medicine. Sci Rep (2016) 0.75
Autocrine and Paracrine Interactions between Multiple Myeloma Cells and Bone Marrow Stromal Cells by Growth Arrest-specific Gene 6 Cross-talk with Interleukin-6. J Biol Chem (2017) 0.75
Artocarpus altilis CG-901 alters critical nodes in the JH1-kinase domain of Janus kinase 2 affecting upstream JAK/STAT3 signaling. J Mol Model (2015) 0.75
Identification of novel inhibitors of human Chk1 using pharmacophore-based virtual screening and their evaluation as potential anti-cancer agents. J Comput Aided Mol Des (2014) 0.75
Loss of FAM46C promotes cell survival in myeloma. Cancer Res (2017) 0.75
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
BRAF mutation predicts sensitivity to MEK inhibition. Nature (2005) 17.14
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med (2008) 14.47
Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov (2006) 14.01
Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem (1998) 13.93
A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci U S A (1995) 10.25
Proteins regulating Ras and its relatives. Nature (1993) 9.87
ERKs: a family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF. Cell (1991) 9.54
The molecular classification of multiple myeloma. Blood (2006) 8.77
RAS oncogenes: the first 30 years. Nat Rev Cancer (2003) 8.61
MAP kinase signalling pathways in cancer. Oncogene (2007) 8.52
Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med (1999) 7.97
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta (2006) 7.33
Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol (2004) 6.61
Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res (2007) 5.59
The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors (2006) 5.58
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer (2007) 5.57
Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol (2008) 4.82
Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim. J Biol Chem (2003) 4.55
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood (2010) 4.52
Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat Struct Mol Biol (2004) 4.40
Identification of the sites in MAP kinase kinase-1 phosphorylated by p74raf-1. EMBO J (1994) 4.37
Dual specificity phosphatases: a gene family for control of MAP kinase function. FASEB J (2000) 3.99
Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244). Cancer Res (2010) 3.54
Modulation of signalling by Sprouty: a developing story. Nat Rev Mol Cell Biol (2004) 3.46
GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin Cancer Res (2011) 3.36
Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene (1999) 3.32
BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Sci Signal (2010) 3.25
Dual-specificity MAP kinase phosphatases (MKPs) and cancer. Cancer Metastasis Rev (2008) 2.94
Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging (Albany NY) (2011) 2.72
The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. Clin Cancer Res (2008) 2.64
MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol. Oncogene (2004) 2.62
Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. Blood (2001) 2.48
Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases. J Biol Chem (1997) 2.47
Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol (2005) 2.32
Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers. Clin Cancer Res (2010) 2.31
Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia (2005) 2.30
Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia (2008) 2.29
Antimyeloma activity of heat shock protein-90 inhibition. Blood (2005) 2.24
Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma. Mol Cancer Ther (2007) 2.01
A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer. Clin Cancer Res (2010) 1.95
Tumor progression locus 2 (Tpl-2) encodes a protein kinase involved in the progression of rodent T-cell lymphomas and in T-cell activation. Proc Natl Acad Sci U S A (1993) 1.95
Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood (2003) 1.92
Conditionally oncogenic forms of the A-Raf and B-Raf protein kinases display different biological and biochemical properties in NIH 3T3 cells. Mol Cell Biol (1995) 1.87
A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression. Blood (2010) 1.82
High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis. Hum Mutat (2001) 1.80
Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response. Clin Cancer Res (2010) 1.77
Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells. Sci Signal (2011) 1.77
Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo. Br J Haematol (2010) 1.73
A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens. J Thorac Oncol (2010) 1.72
Pharmacodynamic and toxicokinetic evaluation of the novel MEK inhibitor, PD0325901, in the rat following oral and intravenous administration. Cancer Chemother Pharmacol (2006) 1.71
A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens. Invest New Drugs (2010) 1.62
Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis. Blood (2007) 1.60
The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo. Leuk Res (2010) 1.59
Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors. Blood (2004) 1.57
Clinical and biological significance of RAS mutations in multiple myeloma. Leukemia (2008) 1.56
Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial. Blood (1996) 1.54
Signalling and survival pathways in multiple myeloma. Eur J Cancer (2006) 1.52
Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma. J Clin Oncol (2011) 1.52
A Mek1-Mek2 heterodimer determines the strength and duration of the Erk signal. Nat Struct Mol Biol (2009) 1.48
Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines. Int J Cancer (2009) 1.44
Identification of the MEK1(F129L) activating mutation as a potential mechanism of acquired resistance to MEK inhibition in human cancers carrying the B-RafV600E mutation. Cancer Res (2011) 1.40
In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma. Haematologica (2009) 1.38
RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer. Cancer Res (2009) 1.38
Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells. Mol Cancer Ther (2009) 1.32
Targeting Hsp90 for the treatment of cancer. Curr Opin Drug Discov Devel (2006) 1.32
The use of novel agents in the treatment of relapsed and refractory multiple myeloma. Leukemia (2009) 1.30
PD0325901, a mitogen-activated protein kinase kinase inhibitor, produces ocular toxicity in a rabbit animal model of retinal vein occlusion. J Ocul Pharmacol Ther (2009) 1.30
IκB kinase regulation of the TPL-2/ERK MAPK pathway. Immunol Rev (2012) 1.29
STAT3 mediates resistance to MEK inhibitor through microRNA miR-17. Cancer Res (2011) 1.24
Synergistic interactions between MEK1/2 and histone deacetylase inhibitors in BCR/ABL+ human leukemia cells. Leukemia (2005) 1.21
KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: implication for combinatorial approach. Mol Carcinog (2010) 1.18
Ras oncogene mutation in multiple myeloma. J Exp Med (1989) 1.11
PI3-K/AKT/FKHR and MAPK signaling cascades are redundantly stimulated by a variety of cytokines and contribute independently to proliferation and survival of multiple myeloma cells. Leukemia (2004) 1.11
Mechanistic principles of RAF kinase signaling. Cell Mol Life Sci (2010) 1.07
Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance. Leukemia (2008) 1.05
Targeting HSP 90 induces apoptosis and inhibits critical survival and proliferation pathways in multiple myeloma. Mol Cancer Ther (2011) 1.03
AZD6244 and doxorubicin induce growth suppression and apoptosis in mouse models of hepatocellular carcinoma. Mol Cancer Ther (2007) 1.00
Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. Cancer (2010) 0.96
Targeting MEK1/2 blocks osteoclast differentiation, function and cytokine secretion in multiple myeloma. Br J Haematol (2007) 0.95
BRAF gene is not mutated in plasma cell leukemia and multiple myeloma. Leukemia (2003) 0.94
Blockade of the ERK or PI3K-Akt signaling pathway enhances the cytotoxicity of histone deacetylase inhibitors in tumor cells resistant to gefitinib or imatinib. Biochem Biophys Res Commun (2009) 0.92
Inhibition of MEK signaling enhances the ability of cytarabine to induce growth arrest and apoptosis of acute myelogenous leukemia cells. Apoptosis (2009) 0.90
Sequence-dependent potentiation of paclitaxel-mediated apoptosis in human leukemia cells by inhibitors of the mitogen-activated protein kinase kinase/mitogen-activated protein kinase pathway. Mol Pharmacol (2001) 0.89
Therapeutic approaches for newly diagnosed multiple myeloma patients in the era of novel drugs. Eur J Haematol (2010) 0.81
Sequence of the murine and human cellular myc oncogenes and two modes of myc transcription resulting from chromosome translocation in B lymphoid tumours. EMBO J (1983) 5.93
Mice lacking the c-rel proto-oncogene exhibit defects in lymphocyte proliferation, humoral immunity, and interleukin-2 expression. Genes Dev (1995) 5.51
Cellular myc oncogene is altered by chromosome translocation to an immunoglobulin locus in murine plasmacytomas and is rearranged similarly in human Burkitt lymphomas. Proc Natl Acad Sci U S A (1983) 3.40
Rel-dependent induction of A1 transcription is required to protect B cells from antigen receptor ligation-induced apoptosis. Genes Dev (1999) 2.82
Translocation of the myc cellular oncogene to the immunoglobulin heavy chain locus in murine plasmacytomas is an imprecise reciprocal exchange. Cell (1984) 2.60
High-dose cytarabine (24 g/m2) in combination with idarubicin (HiDAC-3) results in high first-cycle response with limited gastrointestinal toxicity in adult acute myeloid leukaemia. Intern Med J (2013) 2.53
Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia (2009) 2.25
Topical or oral ibuprofen for chronic knee pain in older people. The TOIB study. Health Technol Assess (2008) 2.24
Marginal costs and benefits. BMJ (1996) 2.22
Transcriptionally active DNA region that rearranges frequently in murine lymphoid tumors. Proc Natl Acad Sci U S A (1982) 2.16
How far does screening women for domestic (partner) violence in different health-care settings meet criteria for a screening programme? Systematic reviews of nine UK National Screening Committee criteria. Health Technol Assess (2009) 2.03
B lymphocytes differentially use the Rel and nuclear factor kappaB1 (NF-kappaB1) transcription factors to regulate cell cycle progression and apoptosis in quiescent and mitogen-activated cells. J Exp Med (1998) 2.00
c-Rel regulates interleukin 12 p70 expression in CD8(+) dendritic cells by specifically inducing p35 gene transcription. J Exp Med (2001) 1.92
Rel induces interferon regulatory factor 4 (IRF-4) expression in lymphocytes: modulation of interferon-regulated gene expression by rel/nuclear factor kappaB. J Exp Med (2000) 1.92
Regulation of an essential innate immune response by the p50 subunit of NF-kappaB. J Clin Invest (1998) 1.89
A refined solution structure of hen lysozyme determined using residual dipolar coupling data. Protein Sci (2001) 1.88
Intermittent vascular exclusion of the liver (without vena cava clamping) during major hepatectomy. Br J Surg (1995) 1.88
The anti-apoptotic activities of Rel and RelA required during B-cell maturation involve the regulation of Bcl-2 expression. EMBO J (2000) 1.79
Structural and dynamical properties of a denatured protein. Heteronuclear 3D NMR experiments and theoretical simulations of lysozyme in 8 M urea. Biochemistry (1997) 1.75
Evaluation of four automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Clin Chem (2000) 1.74
Structure of the protein encoded by the chicken proto-oncogene c-myb. Mol Cell Biol (1986) 1.69
Adjuvant rituximab causes prolonged hypogammaglobulinaemia following autologous stem cell transplant for non-Hodgkin's lymphoma. Bone Marrow Transplant (2006) 1.67
A keratin 14 mutational hot spot for epidermolysis bullosa simplex, Dowling-Meara: implications for diagnosis. J Invest Dermatol (1993) 1.64
The subunit composition of NF-kappa B complexes changes during B-cell development. Cell Growth Differ (1994) 1.62
Distinct roles for the NF-kappaB1 (p50) and c-Rel transcription factors in inflammatory arthritis. J Clin Invest (2000) 1.62
Interchromosomal recombination of the cellular oncogene c-myc with the immunoglobulin heavy chain locus in murine plasmacytomas is a reciprocal exchange. EMBO J (1983) 1.57
Oral health-related quality of life of children by dental caries and fluorosis experience. J Public Health Dent (2007) 1.52
Rel/NF-kappaB transcription factors: key mediators of B-cell activation. Immunol Rev (2000) 1.51
Dasl(n)e: the challenge of developing a regional database for autism spectrum disorder. Arch Dis Child (2008) 1.51
Citrate and the conversion of carbohydrate into fat. A comparison of citrate and acetate incorporation into fatty acids. Biochem J (1964) 1.47
Amyloid fibril formation and seeding by wild-type human lysozyme and its disease-related mutational variants. J Struct Biol (2000) 1.45
Mechanistic studies of the folding of human lysozyme and the origin of amyloidogenic behavior in its disease-related variants. Biochemistry (1999) 1.44
Beta-blockers to reduce mortality in patients with systolic dysfunction: a meta-analysis. J Fam Pract (2001) 1.44
The combined absence of the transcription factors Rel and RelA leads to multiple hemopoietic cell defects. Proc Natl Acad Sci U S A (1999) 1.43
CD10 positive thyroid marginal zone non-Hodgkin lymphoma. J Clin Pathol (1999) 1.43
Organization of genes and spacers within the mouse immunoglobulin VH locus. J Mol Appl Genet (1981) 1.41
Structure of a mammalian c-rel protein deduced from the nucleotide sequence of murine cDNA clones. Oncogene Res (1989) 1.41
Postoperative hypoxaemia: continuous extradural infusion of bupivacaine and morphine vs patient-controlled analgesia with intravenous morphine. Br J Anaesth (1998) 1.39
Iron supplementation increases prevalence and effects of malaria: report on clinical studies in Papua New Guinea. Trans R Soc Trop Med Hyg (1986) 1.37
rel/NF-kappa B nuclear complexes that bind kB sites in the murine c-rel promoter are required for constitutive c-rel transcription in B-cells. Cell Growth Differ (1993) 1.36
Affective exchanges between young autistic children and their mothers. J Abnorm Child Psychol (1990) 1.34
NF-kappa B RelA (p65) is essential for TNF-alpha-induced fas expression but dispensable for both TCR-induced expression and activation-induced cell death. J Immunol (2001) 1.32
International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia (2009) 1.29
Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies. Leukemia (2013) 1.20
Organization and expression of murine immunoglobulin genes. Immunol Rev (1981) 1.17
Side-chain conformations in an unfolded protein: chi1 distributions in denatured hen lysozyme determined by heteronuclear 13C, 15N NMR spectroscopy. J Mol Biol (1999) 1.15
A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma. Ann Oncol (2007) 1.14
Children in lesbian and single-parent households: psychosexual and psychiatric appraisal. J Child Psychol Psychiatry (1983) 1.14
Knowledge and acceptability of the HPV vaccine by school children and their parents in Birmingham. Vaccine (2009) 1.12
The murine c-rel proto-oncogene encodes two mRNAs the expression of which is modulated by lymphoid stimuli. Oncogene Res (1990) 1.10
Murine c-rel transcription is rapidly induced in T-cells and fibroblasts by mitogenic agents and the phorbol ester 12-O-tetradecanoylphorbol-13-acetate. Cell Growth Differ (1990) 1.07
Mice lacking the transcription factor subunit Rel can clear an influenza infection and have functional anti-viral cytotoxic T cells but do not develop an optimal antibody response. Int Immunol (1999) 1.07
Exercise for depression in care home residents: a randomised controlled trial with cost-effectiveness analysis (OPERA). Health Technol Assess (2013) 1.05
Validity of autism diagnoses using administrative health data. Chronic Dis Can (2009) 1.03
Non-invasive in vivo near-infrared optical measurement of the penetration depth in the neonatal head. Clin Phys Physiol Meas (1991) 1.02
New insights into the roles of ReL/NF-kappa B transcription factors in immune function, hemopoiesis and human disease. Int J Biochem Cell Biol (1999) 1.02
Activation of the mitogen-activated protein kinase pathway induces transcription of the PAC-1 phosphatase gene. Mol Cell Biol (1996) 1.01
Cloned embryonic DNA sequences flanking the mouse immunoglobulin C gamma 3 and C gamma 1 genes. Nucleic Acids Res (1980) 1.00
The use of the polymerase chain reaction in plant transformation studies. Plant Cell Rep (1991) 0.99
Histology of the postoperative stomach before and after diversion of bile. Br Med J (Clin Res Ed) (1983) 0.97
Closure of gastrojejunostomy for the relief of post-vagotomy symptoms. Br J Surg (1978) 0.97
relA gene control of the synthesis of lipid A fatty acyl moieties. J Bacteriol (1977) 0.97
The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategies. Blood Cancer J (2012) 0.97
Activation of immunoglobulin mu gene expression involves stepwise demethylation. EMBO J (1984) 0.96
Changing microbial epidemiology in hematopoietic stem cell transplant recipients: increasing resistance over a 9-year period. Transpl Infect Dis (2014) 0.94
Repeat hepatectomy for cancer. Br J Surg (1993) 0.94
High-dose gamma-globulin therapy in the reactive haemophagocytic syndrome. Br J Haematol (1994) 0.94
TRAIL-induced eradication of primary tumour cells from multiple myeloma patient bone marrows is not related to TRAIL receptor expression or prior chemotherapy. Leukemia (2001) 0.93
The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells. Leukemia (2011) 0.93
Alternative splicing of RNA transcripts encoded by the murine p105 NF-kappa B gene generates I kappa B gamma isoforms with different inhibitory activities. Proc Natl Acad Sci U S A (1994) 0.93
Graft-versus-lymphoma effect in refractory cutaneous T-cell lymphoma after reduced-intensity HLA-matched sibling allogeneic stem cell transplantation. Bone Marrow Transplant (2004) 0.92
Paranasal sinusitis following allogeneic bone marrow transplant. Bone Marrow Transplant (1997) 0.92
Lack of evidence of disease contamination in ovarian tissue harvested for cryopreservation from patients with Hodgkin lymphoma and analysis of factors predictive of oocyte yield. Br J Cancer (2006) 0.91
Characterization of the structure and dynamics of amyloidogenic variants of human lysozyme by NMR spectroscopy. Protein Sci (2001) 0.91
Alternate RNA splicing of murine nfkb1 generates a nuclear isoform of the p50 precursor NF-kappa B1 that can function as a transactivator of NF-kappa B-regulated transcription. Mol Cell Biol (1994) 0.90
Loss of the BH3-only protein Bid does not rescue RelA-deficient embryos from TNF-R1-mediated fatal hepatocyte destruction. Cell Death Differ (2006) 0.90
Platelet activation during exercise induced asthma: effect of prophylaxis with cromoglycate and salbutamol. Thorax (1986) 0.90
PU.1/Spi-B regulation of c-rel is essential for mature B cell survival. Immunity (2001) 0.89
Fluoxetine vs placebo for depressive symptoms after stroke: failed randomised controlled trial. Int J Geriatr Psychiatry (2007) 0.89
Primers for exon-specific amplification of the KRT5 gene: identification of novel and recurrent mutations in epidermolysis bullosa simplex patients. J Invest Dermatol (1997) 0.88
Cimetidine for recurrent ulcer after vagotomy or gastrectomy: a randomised controlled trial. Br Med J (1978) 0.88
1,3,5-Trialkyl-2,4,6-triiodobenzenes: novel X-ray contrast agents for gastrointestinal imaging. J Med Chem (2000) 0.87
Cystoid macular oedema in chronic myeloid leukaemia: treatment with acetazolamide and response to bone marrow transplantation. Eye (Lond) (1996) 0.87
Periarteritis in a beagle colony. J Comp Pathol (1987) 0.86
The nephrotic syndrome in a heifer due to glomerulonephritis. Res Vet Sci (1980) 0.86
Intestinal protozoa and intestinal helminthic infections in displacement camps in Sierra Leone. Afr J Med Med Sci (2007) 0.86
Clinical relevance of the minor histocompatibility antigen HA-1 in allogeneic bone marrow transplantation between HLA identical siblings. Transplant Proc (2001) 0.85
Cost-effectiveness of advising the use of topical or oral ibuprofen for knee pain; the TOIB study [ISRCTN: 79353052]. Rheumatology (Oxford) (2008) 0.84
Allo-SCT for hematological malignancies in the setting of HIV. Bone Marrow Transplant (2009) 0.84
RNA splicing generates alternate forms of germline immunoglobulin alpha heavy chain transcripts. Int Immunol (1990) 0.84
Emmetropisation, axial length, and corneal topography in teenagers with Down's syndrome. Br J Ophthalmol (1998) 0.83
Bcl-2 transgene expression fails to prevent fatal hepatocyte apoptosis induced by endogenous TNFalpha in mice lacking RelA. Cell Death Differ (2006) 0.81
Metastatic spinal cord compression as a result of the unknown primary tumour. Eur Spine J (2014) 0.80
A common keratin 5 gene mutation in epidermolysis bullosa simplex--Weber-Cockayne. J Invest Dermatol (1995) 0.80
Getting guidelines to work in practice. Arch Dis Child (2007) 0.80
The transcriptional regulator Rel is essential for antigen receptor-mediated stimulation of mature T cells but dispensable for positive and negative selection of thymocytes and T cell apoptosis. Eur J Immunol (1999) 0.80
Reduced-intensity conditioned allogeneic haematopoietic stem cell transplantation results in durable disease-free and overall survival in patients with poor prognosis myeloid and lymphoid malignancies: eighty-month follow-up. Bone Marrow Transplant (2009) 0.79